Long-term angiogenic and thromboinflammatory signatures in post-COVID-19 syndrome

Angiogenesis. 2026 Aug 7;29(4):55. doi: 10.1007/s10456-026-10075-3.ABSTRACTBACKGROUND: Post-COVID-19 syndrome is a major long-term sequela of severe SARS-CoV-2 infection, potentially involving persistent angiogenic and thromboinflammatory dysfunction, though long-term biomarker behavior remains uncl

A Arlette Araceli Mora Zetina

Metabolic reprogramming drives pancreatic β cell neogenesis from α cells

Nat Chem Biol. 2026 Aug 7. doi: 10.1038/s41589-026-02293-z. Online ahead of print.ABSTRACTLoss of functional β cells is a hallmark of diabetes, and restoring β cell mass remains a critical goal in the quest for a specific therapy. One potential strategy is to convert non-β cells in the islet, such a

Y Yufeng Zhang

STOP-RIO study: protocol for a randomised, controlled, open-label non-inferiority trial to test the safety of discontinuation of riociguat after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension

BMJ Open. 2026 Aug 7;16(8):e120820. doi: 10.1136/bmjopen-2026-120820.ABSTRACTINTRODUCTION: Balloon pulmonary angioplasty (BPA) improves haemodynamics and outcomes in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Riociguat is frequently initiated before BPA to reduce

T Tamara Carina Rodenburg